The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Current and Future Development in Lung Cancer Diagnosis
Open accessAbstract
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 1×
“liquid biopsy, primarily plasma-based circulating tumor DNA (ctDNA) assays, and whether ctDNA can now replace a biopsy or recurrent biopsies in some clinical settings [39,40].”
BackgroundLiquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 4×
“The first discovery of circulating DNA and RNA in the plasma of healthy and sick individuals commenced in 1948 [55].”
BackgroundInfluentialNovello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Cancer epigenomics: DNA methylomes and histone-modification maps
Esteller, M. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2005 · Cited by 2,146
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Progress and prospects of early detection in lung cancer
Blandin Knight, S., Crosbie, P. A., Balata, H., Chudziak, J., Hussell, T., & Dive, C. (2017) · Open Biology · doi:10.1098/rsob.170070 · Cited by 935
Microsatellite alterations in plasma DNA of small cell lung cancer patients
Qi Chen, X., Stroun, M., Magnenat, J.-L., Nicod, L. P., Kurt, A.-M., Lyautey, J., Lederrey, C., & Anker, P. (1996) · Nature Medicine · doi:10.1038/nm0996-1033 · Cited by 647
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Wood, D. E., Kazerooni, E. A., Baum, S. L., Eapen, G. A., Ettinger, D. S., Hou, L., Jackman, D. M., Klippenstein, D., Kumar, R., Lackner, R. P., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0020 · Cited by 611
Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer
Spira, A., Beane, J. E., Shah, V., Steiling, K., Liu, G., Schembri, F., Gilman, S., Dumas, Y.-M., Calner, P., Sebastiani, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1556 · Cited by 572
Horeweg, N., Scholten, E. T., de Jong, P. A., van der Aalst, C. M., Weenink, C., Lammers, J.-W. J., Nackaerts, K., Vliegenthart, R., ten Haaf, K., Yousaf-Khan, U. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70387-0 · Cited by 384
Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer
Xie, Y., Todd, N. W., Liu, Z., Zhan, M., Fang, H., Peng, H., Alattar, M., Deepak, J., Stass, S. A., & Jiang, F. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.004 · Cited by 316
Pennell, N. A., Arcila, M. E., Gandara, D. R., & West, H. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237863 · Cited by 310
Travis, W. D. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.150 · Cited by 294
The detection of EpCAM+ and EpCAM– circulating tumor cells
Wit, S. D., Dalum, G. V., Lenferink, A. T. M., Tibbe, A. G. J., Hiltermann, T. J. N., Groen, H. J. M., van Rijn, C. J. M., & Terstappen, L. W. M. M. (2015) · Scientific Reports · doi:10.1038/srep12270 · Cited by 293
Survival and Mortality from Lung Cancer in a Screened Population
Tockman, M. S. (1986) · Chest · doi:10.1378/chest.89.4_supplement.324s-a · Cited by 275
Kulpa, J., Wójcik, E., Reinfuss, M., & Kołodziejski, L. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.11.1931 · Cited by 242
Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer
Okamura, K., Takayama, K., Izumi, M., Harada, T., Furuyama, K., & Nakanishi, Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.002 · Cited by 237
Manser, R., Lethaby, A., Irving, L. B., Stone, C., Byrnes, G., Abramson, M. J., & Campbell, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001991.pub3 · Cited by 233
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz245 · Cited by 224
Hsu, P.-C., Jablons, D. M., Yang, C.-T., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 205
Matsui, I., Wiegand, L., & Pegg, A. E. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69802-9 · Cited by 195
Lung Cancer Screening: Advantages, Controversies, and Applications
Nanavaty, P., Alvarez, M. S., & Alberts, W. M. (2014) · Cancer Control · doi:10.1177/107327481402100102 · Cited by 165
Showe, M. K., Vachani, A., Kossenkov, A. V., Yousef, M., Nichols, C., Nikonova, E. V., Chang, C., Kucharczuk, J. C., Tran, B. G., Wakeam, E., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1378 · Cited by 161
Cyfra 21-1 as a Biologic Marker of Non-small Cell Lung Cancer
Wieskopf, B., Demangeat, C., Purohit, A., Stenger, R., Gries, P., Kreisman, H., & Quoix, E. (1995) · Chest · doi:10.1378/chest.108.1.163 · Cited by 159
Chemotherapy advances in small-cell lung cancer.
Chan, B. A., & Coward, J. I. G. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.07.43 · Cited by 155
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 149
Liu, Y., Qing Lan, B., Siegfried, J. M., Luketich, J. D., & Keohavong, P. (2006) · Neoplasia · doi:10.1593/neo.05586 · Cited by 140
Alborelli, I., Generali, D., Jermann, P. M., Cappelletti, M. R., Ferrero, G., Scaggiante, B., Bortul, M., Zanconati, F., Nicolet, S., Haegele, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1770-3 · Cited by 140
Human sweat metabolomics for lung cancer screening
Calderón-Santiago, M., Priego‐Capote, F., Turck, N., Robin, X., Gámez, B. J., Sanchez, J., & de Castro, M. D. L. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-8700-8 · Cited by 138
Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer
Paci, M., Maramotti, S., Bellesia, E., Formisano, D., Albertazzi, L., Ricchetti, T., Ferrari, G., Annessi, V., Lasagni, D., Carbonelli, C. M., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.07.012 · Cited by 133
Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography
Toyoda, Y., Nakayama, T., Kusunoki, Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604351 · Cited by 127
Screening for lung cancer: A systematic review and meta-analysis
Ali, M. U., Miller, J., Peirson, L., Fitzpatrick‐Lewis, D., Kenny, M., Sherifali, D., & Raina, P. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.04.015 · Cited by 127
Molecular sputum analysis for the diagnosis of lung cancer
Hubers, A. J., Prinsen, C., Sozzi, G., Lissenberg-Witte, B. I., & Thunnissen, E. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.393 · Cited by 115
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Kim, E. Y., Kim, A., Kim, S. K., & Chang, Y. S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.006 · Cited by 113
Bertolini, G., D’Amico, L., Moro, M., Landoni, E., Perego, P., Miceli, R., Gatti, L., Andriani, F., Wong, D., Caserini, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3781 · Cited by 105
Serum and blood based biomarkers for lung cancer screening: a systematic review
Chu, G. C. W., Lazare, K., & Sullivan, F. (2018) · BMC Cancer · doi:10.1186/s12885-018-4024-3 · Cited by 92
A Gene Expression Signature from Peripheral Whole Blood for Stage I Lung Adenocarcinoma
Rotunno, M., Hu, N., Su, H., Wang, C., Goldstein, A. M., Bergen, A. W., Consonni, D., Pesatori, A. C., Bertazzi, P. A., Wacholder, S., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0170 · Cited by 89
Zhang, R., Shao, F., Wu, X., & Ying, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.11.009 · Cited by 86
Tumor molecular profiling of NSCLC patients using next generation sequencing
Τσούλος, Ν., Papadopoulou, E., Metaxa-Mariatou, V., Tsaousis, G., Efstathiadou, C., Tounta, G., Scapeti, A., Bourkoula, E., Zarogoulidis, P., Pentheroudakis, G. E., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.6051 · Cited by 81
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Horn, L., Reck, M., & Spigel, D. R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0523 · Cited by 80
The metabolomic detection of lung cancer biomarkers in sputum
Cameron, S. J. S., Lewis, K. E., Beckmann, M., Allison, G. G., Ghosal, R., Lewis, P. D., & Mur, L. A. J. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.02.006 · Cited by 78
A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection
Zhang, L., Zheng, J., Ahmed, R., Huang, G., Reid, J., Mandal, R., Maksymuik, A., SITAR, D. S., Tappia, P. S., Ramjiawan, B., et al. (2020) · Cancers · doi:10.3390/cancers12030622 · Cited by 73
Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer
Zander, T., Hofmann, A., Staratschek‐Jox, A., Claßen, S., Debey‐Pascher, S., Maisel, D., Ansén, S., Hahn, M., Beyer, M., Thomas, R. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0533 · Cited by 69
Serum and Plasma Metabolomic Biomarkers for Lung Cancer
Kumar, N., Shahjaman, M., Mollah, M. N. H., Islam, S. M. S., & Hoque, M. A. (2017) · Bioinformation · doi:10.6026/97320630013202 · Cited by 63
Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients
Keller, A., Backes, C., Leidinger, P., Kefer, N., Boisguérin, V., Bárbácioru, C., Vogel, B., Matzas, M., Huwer, H., Katus, H. A., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05353a · Cited by 60
Swanton, C., Venn, O., Aravanis, A., Hubbell, E., Maddala, T., Beausang, J. F., Filippova, D., Gross, S., Jamshidi, A., Shen, L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12003 · Cited by 57 · cited 1×
“These mutations originate from clonal hematopoiesis of indeterminate potential (CHIP) as a result of somatic mutations acquired with age [42].”
BackgroundLiquid biopsy and its role in an advanced clinical trial for lung cancer
Johann, D. J., Steliga, M. A., Shin, I. J., Yoon, D., Arnaoutakis, K., Hutchins, L. F., Liu, M., Liem, J., Walker, K., Pereira, A., et al. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217750087 · Cited by 55
Assessment of serum CYFRA 21-1 in lung cancer
Muraki, M., Tohda, Y., Iwanaga, T., Uejima, H., Nagasaka, Y., & Nakajima, S. (1996) · Cancer · Cited by 44
Non-coding RNAs in lung cancer
Ricciuti, B., Mecca, C., Crinò, L., Baglivo, S., Cenci, M., & Metro, G. (2014) · Oncoscience · doi:10.18632/oncoscience.98 · Cited by 43
Kumar, S., Guleria, R., Singh, V., Bharti, A. C., Mohan, A., & Das, B. C. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.021 · Cited by 43
Melosky, B. L., Cheema, P. K., Brade, A. M., McLeod, D., Liu, G., Wheatley‐Price, P., Jao, K., Schellenberg, D. D., Juergens, R. A., Leighl, N. B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0193 · Cited by 43
Wang, J., Zou, Z., Xia, H., He, J., Zhong, N., & Tao, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032695 · Cited by 42
Angiogenesis and the multistage development of lung cancers.
Gazdar, A. F., & Minna, J. D. (2000) · PubMed · Cited by 29
Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer
Mazzone, P. J., Wang, X., Lim, S. H., Choi, H., Jett, J. R., Vachani, A., Zhang, Q., Beukemann, M., Seeley, M., Martino, R., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1996-0 · Cited by 29
Szpechciński, A., Dancewicz, M., Kopiński, P., Kowalewski, J., & Chorostowska‐Wynimko, J. (2009) · European journal of medical research · doi:10.1186/2047-783x-14-s4-237 · Cited by 21
Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
Wong, S. K., & Iams, W. T. (2021) · Cancers · doi:10.3390/cancers13030506 · Cited by 21
ELISA-based detection of Open Reading Frame protein 1 in patients at risk of developing lung cancer
Sharp, C. N., Korte, E. A., Hosseinnejad, K., Pitman, J., Lavasanifar, A., Eichenberger, D. J., Sephton, S. E., Cash, E. D., & Jortani, S. A. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.04.005 · Cited by 6
Cited by
Huang, S., Yang, J., Shen, N., Xu, Q., & Zhao, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.006 · Cited by 317
Fuzzy Logic Systems for Healthcare Applications
Suzuki, A., & Negishi, E. (2024) · Journal of Biomedical and Sustainable Healthcare Applications · doi:10.53759/0088/jbsha20240401 · Cited by 41
Early Diagnosis of Lung Cancer: The Urgent Need of a Clinical Test
Gasparri, R., Guaglio, A., & Spaggiari, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154398 · Cited by 7
Metadata
- Authors
- Nooreldeen, R., & Bach, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-12
- Volume
- 22
- Issue
- 16
- Pages
- 8661
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3191603129
- Cited by
- 931
- References
- 61
- FWCI
- 77.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.